Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy

被引:73
|
作者
Choueiri, Toni K. [1 ]
Regan, Meredith M. [1 ]
Rosenberg, Jonathan E. [1 ]
Oh, William K. [1 ]
Clement, Jessica [1 ]
Amato, Angela M. [1 ]
McDermott, David [1 ]
Cho, Daniel C. [1 ]
Atkins, Michael B. [1 ]
Signoretti, Sabina [1 ]
机构
[1] Dana Farber Harvard Canc Ctr, Renal Canc Program, Boston, MA USA
关键词
renal cell cancer; vascular endothelial growth factor; carbonic anhydrase IX; pathological features; INTERFERON-ALPHA; EXPRESSION; SURVIVAL;
D O I
10.1111/j.1464-410X.2010.09218.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To investigate the utility of tumour carbonic anhydrase IX (CAIX) expression and histological features for predicting the outcome in patients with metastatic clear-cell renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy. PATIENTS AND METHODS We identified 118 patients with mRCC initiating first-line VEGF-targeted therapy, including 94 with clinical and histological data, and available tissue. The primary endpoint was to detect an interaction between sorafenib vs sunitinib treatment and CAIX status on tumour shrinkage. Other treatment outcomes were also assessed. RESULTS There was heterogeneity in tumour responsiveness to sunitinib or sorafenib according to CAIX status; the mean shrinkage was -17% vs -25% for sunitinib-treated patients with high vs low tumour CAIX expression, compared to -13% vs +9% for sorafenib-treated patients (P interaction, 0.05). A higher tumour clear-cell component was independently associated with greater tumour shrinkage (P = 0.02), response (P = 0.02) and treatment duration (P = 0.02). CONCLUSIONS Although CAIX expression had no prognostic value in patients with clear-cell mRCC treated with VEGF-targeted therapy, it might be a predictive biomarker for response to sorafenib treatment. Patients with a higher clear-cell component in their tumours are likely to have a superior clinical benefit from VEGF-targeted therapy.
引用
收藏
页码:772 / 778
页数:7
相关论文
共 50 条
  • [1] Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy
    Choueiri, Toni K.
    Garcia, Jorge A.
    Elson, Paul
    Khasawneh, Mohamad
    Usman, Saif
    Golshayan, Ali Reza
    Baz, Rachid C.
    Wood, Laura
    Rini, Brian I.
    Bukowski, Ronald M.
    [J]. CANCER, 2007, 110 (03) : 543 - 550
  • [2] Carbonic Anhydrase 9 Expression Increases with Vascular Endothelial Growth Factor-Targeted Therapy and Is Predictive of Outcome in Metastatic Clear Cell Renal Cancer
    Stewart, Grant D.
    O'Mahony, Fiach C.
    Laird, Alexander
    Rashid, Sukaina
    Martin, Sarah A.
    Eory, Lel
    Lubbock, Alexander L. R.
    Nanda, Jyoti
    O'Donnell, Marie
    Mackay, Alan
    Mullen, Peter
    McNeill, S. Alan
    Riddick, Antony C. P.
    Aitchison, Michael
    Berney, Daniel
    Bex, Axel
    Overton, Ian M.
    Harrison, David J.
    Powles, Thomas
    [J]. EUROPEAN UROLOGY, 2014, 66 (05) : 956 - 963
  • [3] Vascular Endothelial Growth Factor-targeted Therapy in Metastatic Renal Cell Carcinoma
    Rini, Brian I.
    [J]. CANCER, 2009, 115 (10) : 2306 - 2312
  • [4] Prognostic and predictive values of carbonic anhydrase IX (CAIX) and pathologic features in patients with metastatic clear cell renal cell carcinoma receiving targeted therapy
    Choueiri, T. K.
    Regan, M.
    Oh, W.
    Clement, J.
    Amato, A.
    McDermott, D.
    Cho, D.
    Atkins, M.
    Signoretti, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Carbonic anhydrase IX (CA IX) and pathologic features as predictors of outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving VEGF-targeted therapy
    Choueiri, T. K.
    Regan, M. M.
    Brick, A. J.
    Clement, J. M.
    Kwabi, C.
    Shah, K.
    Amato, A.
    McDermott, D. F.
    Atkins, M. B.
    Signoretti, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor-targeted therapy
    Park, Ji Young
    Lee, Jae-Lyun
    Baek, Seunghee
    Eo, Soo-Heang
    Go, Heounjeong
    Ro, Jae Y.
    Cho, Yong Mee
    [J]. HUMAN PATHOLOGY, 2014, 45 (07) : 1437 - 1444
  • [7] Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma Feasibility and Clinical Outcome
    Sadeghi, Sarmad
    Albiges, Laurence
    Wood, Laura S.
    Black, Shari L.
    Gilligan, Timothy D.
    Dreicer, Robert
    Garcia, Jorge A.
    Escudier, Bernard J.
    Rini, Brian I.
    [J]. CANCER, 2012, 118 (13) : 3277 - 3282
  • [8] Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Therapy
    Golshayan, Ali Reza
    George, Saby
    Heng, Daniel Y.
    Elson, Paul
    Wood, Laura S.
    Mekhail, Tarek M.
    Garcia, Jorge A.
    Aydin, Hakan
    Zhou, Ming
    Bukowski, Ronald M.
    Rini, Brian I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (02) : 235 - 241
  • [9] The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy
    Macfarlane, Robyn
    Heng, Daniel Y. C.
    Xie, Wanling
    Knox, Jennifer J.
    McDermott, David F.
    Rini, Brian I.
    Kollmannsberger, Christian
    Choueiri, Toni K.
    [J]. CANCER, 2012, 118 (02) : 365 - 370
  • [10] Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy
    Vickers, Michael M.
    Choueiri, Toni K.
    Rogers, Miranda
    Percy, Andrew
    Finch, Daygen
    Zama, Ivan
    Cheng, Tina
    North, Scott
    Knox, Jennifer J.
    Kollmannsberger, Christian
    McDermott, David F.
    Rini, Brian I.
    Heng, Daniel Y.
    [J]. UROLOGY, 2010, 76 (02) : 430 - 434